Paragon 28 Inc Stock Price, News & Analysis

Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused on foot and ankle orthopedics, announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference. The company's Chairman and CEO, Albert DaCosta, along with CFO Steve Deitsch, will present a fireside chat on September 13, 2022, at 3:30 p.m. ET. A live webcast will be accessible through the investor relations section of their website at ir.paragon28.com.

Paragon 28, Inc. (NYSE: FNA) reported a 19% growth in net revenue for Q2 2022, totaling $42.5 million, driven by increased productivity and new product launches. U.S. revenue was $36.8 million with a similar 19% increase. Internationally, the company achieved record revenue of $5.7 million, up 20%. Despite this growth, Paragon reported a net loss of $9.6 million and raised its 2022 revenue guidance to $176 million. Operating expenses surged to $43.9 million, influenced by one-time costs related to a new SAP launch.

Paragon 28, Inc. (NYSE: FNA), a leader in medical devices for foot and ankle orthopedics, announced that its Chairman and CEO, Albert DaCosta, along with CFO Steve Deitsch, will present at The Canaccord Genuity 42nd Annual Growth Conference in Boston. The fireside chat is scheduled for August 11, 2022, at 1:00 PM Eastern Time. Interested investors can access the live webcast and archived recording via the Company's investor relations website.

Paragon 28, Inc. (NYSE: FNA) will report its second quarter 2022 financial results after market close on August 3, 2022. A conference call will follow at 4:30 p.m. ET, accessible via phone (domestic: 844-200-6205, international: 929-526-1599) with conference ID: 990038, or through a webcast on the company's website. Paragon 28 focuses on innovative orthopedic solutions for foot and ankle conditions, aiming to enhance patient outcomes and reduce complications.

Paragon 28, Inc. (NYSE: FNA) announced the launch of its nationwide mobile training lab tour, aimed at enhancing on-site surgeon education. This mobile lab, housed in a 43x30 foot trailer, can host up to 20 surgeons at a time and will facilitate over 50 training sessions across approximately fifty U.S. cities in the latter half of 2022. CEO Albert DaCosta emphasized the initiative's role in showcasing the company's innovative product portfolio, which includes eight new product launches in 2022.

Paragon 28, Inc. (NYSE: FNA) has launched its Monkey Rings™ Circular External Fixation System, aimed at trauma, deformity correction, and limb salvage. This system utilizes external wires and screws to stabilize bone while preserving soft tissue integrity. CEO Albert DaCosta emphasized the innovation reflects the company's commitment to enhancing patient outcomes. The new product adds to their existing offerings, including the Silverback® Ankle Fusion Plating System and Gorilla® R3CON Plating System, positioning Paragon 28 as a comprehensive solution provider in the foot and ankle orthopedic market.

Paragon 28, Inc. (NYSE: FNA) has announced the launch of its TenoTac™ 2.0 Soft Tissue Fixation System, enhancing its hammertoe and soft-tissue portfolio. The new system features a titanium threaded implant designed for improved capture of soft tissue, streamlined tensioning, and better fit. CEO Albert DaCosta emphasized the device's potential to enhance surgical control and patient outcomes. This launch adds to a diverse range of the company’s existing hammertoe solutions, including the Paratrooper™ Plantar Plate System and Mini-Monster® Screw System.

Paragon 28, Inc. (NYSE: FNA), a prominent medical device company focusing on foot and ankle orthopedics, has launched the Grappler™ Suture Anchor System. This new product aims to enhance surgical procedures by providing surgeons with a reliable fixation option that limits implant migration and loss of tension during tissue reattachment. CEO Albert DaCosta expressed enthusiasm for this expansion, which adds to the company's soft-tissue portfolio that includes products like the Paratrooper™ Plantar Plate System and R3ACT Stabilization System.

Paragon 28, Inc. (NYSE: FNA) reported Q1 2022 net revenue of $41.4 million, a growth of 25% year-over-year. U.S. revenue was $36.0 million with 24% growth, while international revenue reached $5.4 million, up 35%. Gross margin improved to 83.6% from 80.5% despite operating expenses rising to $43.0 million. The company's net loss widened to $9.2 million compared to $0.5 million last year. For 2022, Paragon expects net revenue between $171.0 million and $175.0 million, indicating 16% to 19% growth.